Search
Search Results
##search.searchResults.foundPlural##
-
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3950PDF: 1004HTML: 3553Untitled: 162Cneo. Fig.1: 96Untitled: 87Untitled: 109Untitled: 110 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1958PDF: 1572HTML: 344 -
IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME
3189PDF: 2214HTML: 23283Untitled: 181Untitled: 185Untitled: 207 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1272HTML: 360PDF: 784 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2058PDF: 1510HTML: 247 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1094PDF: 996HTML: 171 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4277PDF: 1562HTML: 3350Tables and Images: 194 -
-
SOLITARY PLASMACYTOMA
3734PDF: 2124HTML: 1186fIGURES 1,2: 186 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1145PDF: 907HTML: 186 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
1944PDF: 881HTML: 122Suppl. Files: 489 -
FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
3228PDF: 1205HTML: 2170 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
8813PDF: 5927HTML: 87436Fig.1b: 159Fig.1c: 164Fig.2a: 154Fig.2b: 154Fig.4: 167Fig.2c: 152Fig.3: 161Tab.1: 208Tab.2: 186Tab.3: 175Tab.4: 194Fig1a: 151 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3417PDF: 2323HTML: 1401 -
-
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1408PDF: 887HTML: 207 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7181PDF: 2344HTML: 1699Table 1.: 181Table 2.: 197Table 3.: 179Table 4.: 177 -
EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
1311PDF: 684Suppl. Files: 294Html: 117 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2719PDF: 971HTML: 5494 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3291PDF: 1239HTML: 2187Fi.1 Gritti.Rambaldi: 182 -
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12218PDF: 1623HTML: 4138Cover letter: 176Figure 1: 171 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2112PDF: 911HTML: 2143 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
376PDF: 196HTML: 70 -
DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.
4628PDF: 1727HTML: 2093 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2064PDF: 1294HTML: 3485 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
3706Suppl. Files: 1026PDF: 1015Html: 101 -
Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited
1038PDF: 814HTML: 217 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
943PDF: 1067Suppl. Files: 548HTML: 71 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4186PDF: 1679HTML: 1094 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2785PDF: 1300HTML: 3549Untitled: 169Untitled: 180Untitled: 157 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1588PDF: 1114HTML: 227 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
1919PDF: 731HTML: 3098 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
1943PDF: 772HTML: 194







